Raymond James Has Optimistic Outlook of TSE:MDP Q1 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Investment analysts at Raymond James raised their Q1 2026 EPS estimates for shares of Medexus Pharmaceuticals in a research report issued to clients and investors on Monday, March 17th. Raymond James analyst M. Freeman now forecasts that the company will earn ($0.20) per share for the quarter, up from their prior forecast of ($0.26). Raymond James currently has a “Strong-Buy” rating and a $4.00 target price on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ FY2026 earnings at ($0.46) EPS.

MDP has been the topic of several other reports. Stifel Nicolaus lowered shares of Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price objective for the stock from C$6.00 to C$3.45 in a research report on Friday, February 7th. Leede Financial upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, January 22nd. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Ventum Financial boosted their price objective on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Finally, Stifel Canada lowered shares of Medexus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of C$5.49.

Medexus Pharmaceuticals Stock Up 8.6 %

TSE:MDP opened at C$2.77 on Wednesday. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$5.56. The firm’s fifty day simple moving average is C$3.35 and its 200-day simple moving average is C$2.92. The stock has a market cap of C$62.02 million, a PE ratio of 13.25 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.